MarginsXMarginsX
Home › Markets › Health Care › CLLS

Cellectis S.A. (CLLS)

CLLS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.04
-11.86% on the day
Market cap
$104.5M
Micro cap
Revenue · 2025
$72.9M
+75.8% on 2024
Net income · 2025
-$67.6M
-92.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1627281/000119312526116428/0001193125-26-116428-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCLLS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryFrance
IPO year2015
SEC CIK0001627281
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inFrance

Financials · 2025

LineValue
Revenue$72.9M
Net income-$67.6M
Operating income-$33.1M
Net margin-92.7%
Operating margin-45.3%
Revenue growth+75.8%
Cash$61.5M
Total assets$324.7M
P/E (computed)Net income was not positive
P/S (computed)1.4×

Warning signs

Cash runway
18.7 months
$61.5M cash at December 31, 2025
Share count, 1 year
See the dilution note
+58.4% over 3 years
Going-concern doubt
Yes
20-F filed March 20, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Cibus' most recent financial statements included in its quarterly report on Form 10-Q for the quarter ended September 31, 2025 note that there is substantial doubt about Cibus' ability to continue as a going concern for at least one year from the date of issuance of those financial statements."
20-F 2026-03-20
Cash and burn$61.5M cash; operating cash flow -$9.9M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG SA, Paris La Défense, FrancePCAOB Form AP 2026-04-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$72.9M-$67.6M-$39.4M$61.5MNo debt tags$72.9M20-F 2026-03-20
FY 2024
2024-12-31
$41.5M-$36.8M$23.0M$143.3MNo debt tags$41.5M20-F 2026-03-20
FY 2023
2023-12-31
$755K-$101.1M-$24.7M$136.7MNo debt tags$755K20-F 2026-03-20
FY 2022
2022-12-31
$19.2M-$106.1M-$87.4M$93.2MNo debt tags$19.2M20-F 2025-03-14
FY 2021
2021-12-31
$30.3M-$114.2M-$104.6M$185.6MNo debt tags$30.3M20-F 2024-04-29
FY 2020
2020-12-31
$51.1M-$81.1M-$80.3M$241.1MNo debt tags$51.1M20-F 2023-03-14
FY 2019
2019-12-31
$15.2M-$102.1M-$69.1M$340.5MNo debt tags$15.2M20-F 2022-03-03
FY 2018
2018-12-31
$12.7M-$78.7M-$68.1M$451.5MNo debt tags$12.7M20-F 2021-03-04

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentF-32025-07-02
Latest annual report20-F2026-03-20
Latest quarterly / interim
FORM 6-K
6-K2026-11-13

Source: SEC EDGAR submissions feed, 538 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+10.3%
1 month+7.3%
3 months-62.9%
Year to date-75.6%
1 year-66.9%
From 52-week high-77.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DERMJourney Medical Corporation$3.70-14.55%$104.5M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
ADAGAdagene Inc.$1.60-6.43%$105.7M
UNCYUnicycive Therapeutics Inc.$3.70+4.23%$103.1M
CUECue Biopharma Inc.$14.10-12.53%$102.4M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier